Lexington-based Concert Pharmaceuticals Inc. has named Gregory Miller as its head of business and corporate development.
Miller previously served as senior director of business development and corporate strategy at AMAG Pharmaceuticals Inc., another Lexington drug maker. Prior to his role at AMAG, Miller served in various corporate development roles at Genzyme Corp., and previously worked in epidemiology and clinical research. Miller graduated from Boston University with a master of public health in epidemiology and biostatistics and from Brandeis University with a bachelor’s degree in psychology.
Miller will join 2009 Mass High Tech All Star Roger Tung, who serves as president and CEO of Concert Pharmaceuticals.
Founded in 2006, Concert Pharmaceuticals develops small molecule drugs intended to treat HIV/AIDS, renal disease and cardiovascular disease. The company has raised more than $110 million in funding from such investors as Brookside Capital Partners Fund, TVM Capital, Three Arch Partners, Fidelity Investments, Skyline Ventures, Flagship Ventures, Adage Capital Management, Greylock Partners, New Leaf Venture Partners, QVT Fund, SR One Ltd., Mediphase Venture Partners, Westfield Capital Management and Alexandria Equities LLC.